case_images: PMC11750990_01
case_images: Pre-treatment 68Ga-DOTATATE PET/CT showing multiple tracer avid liver lesions and a peripancreatic mass. Peripancreatic mass SUVmax was 36.7.
case_images: fonc-14-1432758-g001.jpg
case_images: PMC11750990_01_fonc-14-1432758-g001.jpg
case_images: f1
case_images: The DOTATATE PET/CT can be seen in  Figure 1 .
case_images: Post-chemotherapy 68Ga-DOTATATE PET/CT shows intense radiotracer uptake in the peripancreatic mass and liver lesions, which was not significantly changed compared to pre-treatment PET/CT. SUVmax of the peripancreatic mass was 82.4. There was interval resolution of the prominent activity in the right urinary collecting system.
case_images: fonc-14-1432758-g002.jpg
case_images: PMC11750990_01_fonc-14-1432758-g002.jpg
case_images: f2
case_images: There were no significant changes on the post-chemotherapy images ( Figure 2 ).
case_images: Potassium changes during the second hospitalization. The lowest potassium level measured was 2.4 MEq/L in the early phases of admission (blue arrow).
case_images: fonc-14-1432758-g003.jpg
case_images: PMC11750990_01_fonc-14-1432758-g003.jpg
case_images: f3
case_images: The patient's changes in serum potassium can be seen in  Figure 3 .
case_images: Anterior images of post-treatment lutetium-177 DOTATATE images obtained 5 days after PRRT. Intense uptake was seen in the bulky mass in the peripancreatic region with multiple liver metastases. Of note, octreotide infusion was performed 8 h before PRRT. PRRT, peptide receptor radionuclide therapy.
case_images: fonc-14-1432758-g004.jpg
case_images: PMC11750990_01_fonc-14-1432758-g004.jpg
case_images: f4
case_images: A post-therapy image was obtained on the fifth day after PRRT and can be seen in  Figure 4 .
case_images: Changes in serum VIP levels during the hospitalization. There was a significant decrease in the VIP level after administration of PRRT. VIP, vasoactive intestinal peptide; PRRT, peptide receptor radionuclide therapy.
case_images: fonc-14-1432758-g005.jpg
case_images: PMC11750990_01_fonc-14-1432758-g005.jpg
case_images: f5
case_images: The serum VIP graph can be seen in  Figure 5 .
case_images: PMC11750990_02
case_images: VIP levels over time in case 1. VIP, vasoactive intestinal peptide.
case_images: fonc-14-1432758-g006.jpg
case_images: PMC11750990_02_fonc-14-1432758-g006.jpg
case_images: f6
case_images: VIP levels over time and after PRRT for case 2. VIP, vasoactive intestinal peptide; PRRT, peptide receptor radionuclide therapy.
case_images: fonc-14-1432758-g007.jpg
case_images: PMC11750990_02_fonc-14-1432758-g007.jpg
case_images: f7
case_images: There was a decrease in the size of the pancreatic tail mass and resolution of the left retroperitoneal lymph node ( Figure 7 ).
case_images: Post-chemotherapy 68Ga-DOTATATE PET/CT showing multiple tracer avid liver lesions and a peripancreatic mass.
case_images: fonc-14-1432758-g008.jpg
case_images: PMC11750990_02_fonc-14-1432758-g008.jpg
case_images: f8